Trial Profile
Efficacy and safety of glecaprevir and pibrentasvir in chronic hepatitis C patients with hemodialysis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Nov 2018
Price :
$35
*
At a glance
- Drugs Glecaprevir/pibrentasvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 21 Nov 2018 Status changed from recruiting to completed.
- 03 Dec 2017 Status changed from not yet recruiting to recruiting.
- 23 Nov 2017 New trial record